AstraZeneca officials are feeling positive about the future, with enough drugs in production to fuel double-digit submissions and approvals by 2017, reaffirming its promise to grow sales by 75 percent.
The company has 14 Phase III drugs that will account for eight-to-ten approvals over the next two years. Leading the way is the company’s revitalized oncology unit, whose three leading medicines have peak sales potential of more than of $12 billion, management has said.
AstraZeneca is brushing off a failed takeover by Pfizer earlier this year.
